A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
At a glance
- Drugs PF 5221304 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Nov 2017 Planned End Date changed from 29 Nov 2018 to 28 Mar 2019.
- 21 Nov 2017 Planned primary completion date changed from 1 Nov 2018 to 28 Feb 2019.
- 29 Sep 2017 Planned End Date changed from 12 Nov 2018 to 29 Nov 2018.